T. Asami et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6391–6396
6395
Table 3
Supplementary data
Stabilities of metastin analogs in human serum
b
Compound
Residual ratioa
t1/2 (min)
Supplementary data associated with this article can be found, in
0 min
5 min
10 min
15 min
Metastin(45–54)
1
6
66
93.4
86.5
0.9
90.7
86.5
<0.5
85.8
85.3
<0.5
82.7
86.4
<1
75
Stable
References and notes
1. Ohtaki, T.; Shintani, Y.; Honda, S.; Matsumoto, H.; Hori, A.; Kanehashi, K.; Terao,
Y.; Kumano, S.; Takatsu, Y.; Masuda, Y.; Ishibashi, Y.; Watanabe, T.; Asada, M.;
Yamad, T.; Suenaga, M.; Kitada, C.; Usuki, S.; Kurokawa, T.; Onda, H.;
Nishimura, O.; Fujino, M. Nature 2001, 411, 613.
a
Residual ratio was determined after incubation in human serum 1 h at 37 °C
(n = 2).
b
The half-lives of studied analogs were calculated according to pseudo-first-
2. Kotani, M.; Detheux, M.; Vandenbogaerde, A.; Communi, D.; Vanderwinden, J.
M.; De Poul, E.; Bre´ zillon, S.; Tyldesley, R.; Suarez-Huerta, N.; Vandeput, F.;
Blanpain, C.; Schiffmann, S. N.; Vassart, G.; Parmentier, M. J. Biol. Chem. 2001,
276, 34631.
3. Muir, A. I.; Chamberlain, L.; Elshourbagy, N. A.; Michalovich, D.; Moore, D. J.;
Calamari, A.; Szekeres, P. G.; Sarau, H. M.; Chambers, J. K.; Murdock, P.;
Steplewski, K.; Shabon, U.; Miller, J. E.; Middleton, S. E.; Darker, J. G.; Larminie,
C. G. C.; Wilson, S.; Bergsma, D. J.; Emson, P.; Faull, R.; Philpott, K. L.; Harrison,
D. C. J. Biol. Chem. 2001, 276, 28969.
4. Matsui, H.; Takatsu, Y.; Kumano, S.; Matsumoto, H.; Ohtaki, T. Biochem. Biophys.
Res. Commun. 2004, 320, 383.
5. Gottsch, M. L.; Cunningham, M. J.; Smith, J. T.; Popa, S. M.; Acohido, B. V.;
Crowley, W. F.; Seminara, S.; Clifton, D. K.; Steiner, R. A. Endocrinology 2004,
145, 4073.
order kinetic models and optimized using monoexponential regressions.
to metastin(45–54),35,36 suggesting that optimization at residue 47
with L- or D-amino acids would result in novel analogs with both
high [Ca2+]i mobilizing activities and serum stability.
AzaGly51 derivatives substituted with unnatural amino acids for
Trp47, b-cyclohexylalanine (Cha) 9, b-(4-pyridyl)alanine [Pya(4)]
11, and b-(2-naphthyl)alanine [Nal(2)] 12 analogs demonstrated
comparable [Ca2+]i-mobilizing activities compared with Trp analog
5 (Table 2). Of these analogs, Nal(2) analog 12 showed the highest
activity and was nearly equivalent to that of metastin(45–54).
However, the residual ratios of these compounds was less than
6. Dhillo, W. S.; Chaudhri, O. B.; Patterson, M.; Thompson, E. L.; Murphy, K. G.;
Badman, M. K.; McGowan, B. M.; Amber, V.; Patel, S.; Ghatei, M. A.; Bloom, S. R.
J. Clin. Endocrinol. Metab. 2005, 90, 6609.
50%. Other L-amino acid substitutions such as threonine (Thr) 7,
7. Thompson, E. L.; Murphy, K. G.; Patterson, M.; Bewick, G. A.; Stamp, G. W.;
Curtis, A. E.; Cooke, J. H.; Jethwa, P. H.; Todd, J. F.; Ghatei, M. A.; Bloom, S. R. Am.
J. Physiol. Endocrinol. Metab. 2006, 291, 1074.
8. Tomita, K.; Oishi, S.; Ohno, H.; Peiper, S. C.; Fujii, N. J. Med. Chem. 2008, 51,
7645.
9. Asami, T.; Nishizawa, N.; Ishibashi, Y.; Nishibori, K.; Horikoshi, Y.; Nakayama,
M.; Tarui, N.; Matsumoto, H.; Ohtaki, T.; Kitada, C. Unpublished results.
10. Mosberg, H. I.; Hurst, R.; Hruby, V. J.; Gee, K.; Yamamura, H. I.; Galligan, J. J.;
Burks, T. F. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 5871.
11. Dooley, C. T.; Chung, N. N.; Wilkes, B. C.; Schiller, P. W.; Bidlack, J. M.;
Pasternak, G. W.; Houghten, R. N. Science 1994, 266, 2019.
12. (a) Spatola, A. F. In Chemistry and Biochemistry of Amino Acids, Peptides, and
Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; pp 267–357; (b)
Sherman, D. B.; Spatola, A. F. J. Am. Chem. Soc. 1990, 112, 433; (c) Hirschmann,
R. Angew. Chem., Int. Ed. Engl. 1990, 29, 1278; (d) Gante, J. Angew. Chem. Int. Ed.
Engl. 1994, 33, 1699.
isoleucine (Ile) 8, and b-(3-pyridyl)alanine [Pya(3)] 10, showed de-
creased agonistic activities compared to metastin(45–54),
although the residual ratios of peptides 7 and 10 were above 50%
in serum stability studies.
As for
analogs exhibited good receptor binding affinity, which were com-
parable to the corresponding -form amino acid derivatives 5 and
11. This result suggested that the stereochemistry of the -carbon
at position 47 does not play a critical role in KISS1R recognition, as
expected. In addition, -Trp analog 13 showed excellent serum sta-
D-amino acid substitutions, D D
-Trp47 13 and -Pya(4)47 14
L
a
D
bility with a residual ratio of 56.4%, compared to 39.5% for Trp ana-
log 5.
In summary, we designed and synthesized metabolically stable
KISS1R decapeptides with selected substitutions at positions 47,
50, and 51. Replacement of Gly with an azaGly residue, which in-
13. (a) Michel, A. G.; Ameziane-Hassani, C.; Boulay, G. Can. J. Chem. 1989, 67, 1312;
(b) Mock, W. L.; Chen, J. T.; Tsang, J. W. Biochem. Biophys. Res. Commun. 1981,
102, 389.
14. Clausen, K.; Spatola, A. F.; Lemieux, C.; Schiller, P. W.; Lawesson, S.-O. Biochem.
Biophys. Res. Commun. 1984, 120, 305.
volved a simple nitrogen atom replacement of an
a-carbon at
15. Meyer, J.-P.; Davis, P.; Lee, K. B.; Porreca, F.; Yamamura, H. I.; Hruby, V. J. J. Med.
Chem. 1995, 38, 3462.
16. Fehrentz, J.-A.; Castro, B. Synthesis 1983, 676.
Gly, resulted in good agonistic activity for KISS1R. This indicated
that some b-turn conformations, which are reported to be observed
in aza peptides, may contribute to interactions with KISS1R. Addi-
tionally, incorporation of the azaGly51 residue improved metabolic
stability of the Phe50-Gly51 and Gly51-Leu52 bonds, which were
resistant to serum proteases such as chymotrypsin, NEP, and
MMP-9. Although a variety of aza amino acid analogs of biologi-
cally active peptides has been reported with improved biological
potency,37–49 this study is the first report that aza amino acid
replacement is a simple way to protect both fragile amide bonds
at the N-terminal and C-terminal of the aza amino acid residue.
Substitution of Trp at position 47 with other amino acids, exem-
plified in this series of analogs with azaGly51, produced several
analogs that were stable to metabolic degradation. Our study dem-
onstrated that the key amino acid replacement with azaGly51 re-
sulted in metabolically stable analogs that could be easily
synthesized using solid-phase methodology without preparing
dipeptide isostere units. Further optimization studies on novel aza-
Gly short length metastin agonists with high potency and meta-
bolic stability are ongoing in prostate cancer drug development.
17. Sasaki, Y.; Coy, D. H. Peptides 1987, 8, 119.
18. Pessi, A.; Pinori, M.; Verdini, A. S.; Viscomi, G. C. Farmaco 1983, 38, 360.
19. Lee, H.-J.; Ahn, I.-A.; Ro, S.; Choi, K.-H.; Choi, Y.-S.; Lee, K.-B. J. Pept. Res. 2000,
56, 35.
´
20. Andre, F.; Vicherat, A.; Boussard, G.; Aubry, A.; Marraud, M. J. Pept. Res. 1997,
50, 372.
21. Zouikri, M.; Vicherat, A.; Aubry, A.; Marraud, M.; Boussard, G. J. Pept. Res. 1998,
52, 19.
22. Lee, H.-J.; Choi, K.-H.; Ahn, I.-A.; Ro, S.; Jang, H. G.; Choi, Y.-S.; Lee, K.-B. J. Mol.
Struct. 2001, 569, 43.
23. Lecoq, A.; Boussard, G.; Marraud, M. Tetrahedron Lett. 1992, 33, 5209.
24. Didierjean, C.; Del Duca, V.; Benedetti, E.; Aubry, A.; Zouikri, M.; Marraud, M.;
Boussard, G. J. Pept. Res. 1997, 50, 451.
25. Andre´, F.; Boussard, G.; Bayeul, D.; Didierjean, C.; Aubry, A.; Marraud, M. J. Pept.
Res. 1997, 49, 556.
26. Benatalah, Z.; Aubry, A.; Boussard, G.; Marraud, M. Int. J. Pept. Protein Res. 1991,
38, 603.
27. Lecoq, A.; Boussard, G.; Marraud, M.; Aubry, A. Biopolymers 1993, 33, 1051.
28. Thormann, M.; Hofmann, H.-J. J. Mol. Struct. 1999, 469, 63.
29. Lee, H.-J.; Song, J.-W.; Choi, Y.-S.; Ro, S.; Yoon, C. Phys. Chem. Chem. Phys. 2001,
3, 1693.
30. Zhang, W. J.; Berglund, A.; Kao, J. L.-F.; Couty, J. P.; Gershengorn, M. C.;
Marshall, G. R. J. Am. Chem. Soc. 2003, 125, 1221.
31. Lee, H. J.; Song, J. W.; Choi, Y. S.; Park, H. M.; Lee, K. B. J. Am. Chem. Soc. 2002,
124, 11881.
32. Lee, J. Y.; Moon, J. S.; Eu, Y. J.; Lee, C. W.; Yang, S. T.; Lee, S. K.; Jung, H. H.; Kim,
H. H.; Rhim, H.; Seong, J. Y.; Kim, J. I. Arch. Biochem. Biophys. 2009, 485, 109.
33. Wilcox, P. E. Methods Enzymol. 1970, 19, 64.
34. Appel, W. Clin. Biochem. 1986, 19, 317.
35. Niida, A.; Wang, Z.; Tomita, K.; Oishi, S.; Tamamura, H.; Otaka, A.; Navenot, J.
M.; Broach, J. R.; Peiper, S. C.; Fujii, N. Bioorg. Med. Chem. Lett. 2006, 16, 134.
Acknowledgements
The authors acknowledge Stephen Mosley of FireKite for edito-
rial assistance in the development of this manuscript which was
supported by Millennium Pharmaceuticals, Inc.